recursion pharmaceuticals valuation
R. Martin Chavez. 03 Wrz. Some biotechs struggle for cash. That’s walking the line between being considered a micro-cap or a small-cap company. Financials. For this and other reasons, Recursion Pharmaceuticals ranks as the 8th most important Utah business story for the 2nd quarter of 2021. It has previously raised a total of $466M from 28 institutional investors including Bayer, Menlo Ventures, CRV, Bill & … It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Recursion Pharmaceuticals (RXRX) stock price, revenue, and financials Recursion Pharmaceuticals market cap is $3.5 b. See All Companies ... For more details on financing and valuation for Recursion Pharmaceuticals, register or login. As explained in the March 30 write-up, Profile. Provides a revolutionary conceptual framework and practical tools to quantify uncertainty and recognize the value of flexibility in real estate development This book takes a practical "engineering" approach to the valuation of options and ... In September 2016, we converted to a Delaware corporation and subsequently changed our name to Recursion Pharmaceuticals, Inc. Found insideIn this groundbreaking book, Markman separates the hype from the reality—explaining with colorful details and informative anecdotes how this convergence amounts to a once-in-a-generation opportunity for investors. Recursion Pharmaceuticals has a post-money valuation in the range of $1B to $10B as of Sep 10, 2020, according to PrivCo. In recent trading, shares of Recursion Pharmaceuticals Inc (RXRX) have crossed above the average analyst 12-month target price of $33.00, changing hands for $33.02/share. Salt Lake City-based Recursion Pharmaceuticals set a goal: discover new treatments for 100 genetic diseases by 2025 using an innovative combination of biology, automation and machine learning. Recursion Pharmaceuticals (RXRX) Analysis Performance Analysts News Valuation Financials Dividends Shorts. With every new discovery, our platform gets smarter, leading to pipeline growth. Valuation: $75 million market cap (via Yahoo Finance) ... Recursion Pharmaceuticals. ... Recursion Pharmaceuticals. Glassdoor gives you an inside look at what it's like to work at Recursion Pharmaceuticals, including salaries, reviews, office photos, and more. Found inside – Page 93VIRCHOW 1999a ) , a valuation may address either the benefits provided by : ( 1 ) certain taxonomic units ( e.g. , crop varieties ... induced by commercialisation of genetic resources , mainly for use by the pharmaceutical industry and plant breeders ( e.g. ... The diversity discussion within environmental economics has been seminally influenced by WEITZMAN ( 1992 ) , who proposed a recursive distance ... 0 comments. Recursion Pharmaceuticals Response We welcome your feedback and are disappointed to hear that your experience working at Recursion isn’t what you had hoped for. Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. Phone 1 385 269-0203. From January 2005 to January 2020, he served in a variety of senior roles at Goldman Sachs, including Chief Information Officer, Chief Financial Officer, and global co-head of the firm’s Securities Division, and was a member of Goldman’s management committee. Found inside... high stock market valuation and finance the development of a drug until it is approved for sale (MA). In both cases, large pharmaceutical companies are ... This is the first book to offer a comprehensive guide to involving patients in health technology assessment (HTA). This work embeds the solvency discussion (and long-term liabilities) into a scientific framework and is intended for researchers as well as practitioners in the financial and actuarial industry, especially those in charge of internal risk ... Actively observing the price movement in … Please enter 2 or more characters. Recursion Pharmaceuticals, LLC, is a Salt Lake City-based drug discovery company founded in 2013 based on technology developed at the University of Utah. Description. A high-level overview of Recursion Pharmaceuticals, Inc. (RXRX) stock. Mathematics and Computation is useful for undergraduate and graduate students in mathematics, computer science, and related fields, as well as researchers and teachers in these fields. Recursion Pharmaceuticals is going bigger than expected in its initial public offering. A synchronized combination of hardware, software and data used to industrialize drug discovery. This book, which displays a distinguished scholar's masterly synthesis of diverse materials, reveals that the Black Death can be considered the cornerstone of the transformation of Europe. The Valuation Handbook offers readers an interesting overview of different issues confronted by the professional (or amateur) valuation practitioner." —Daniel A. Rogers, Associate Professor of Finance, Portland State University "Anybody ... Apple, Microsoft, Intel, Cisco, Yahoo and Google were all start-ups and these success stories show that the phenomenon is not mere speculation. The goal of this book is to show start-ups from a different angle. Found inside – Page 525ROE - 1-1979.02 R A recursive model of dropping out is presented , which attempts to capture separate and interactive effects of capacities ( demand factors ) and opportunities ... Valuation / Efficiency. ... Consumption of pharmaceuticals ,. Recursion is a clinical-stage biotechnology company combining experimental biology and automation with artificial intelligence in a massively parallel system to efficiently discover potential drugs for diverse indications, including genetic disease, inflammation, immunology, and infectious disease. The company uses computer vision to study images of how diseases affect healthy cells and claims to have put together the largest biological image set in the world, as it tracks almost half a million experiments a week. This book synthesizes cutting-edge developments in corporate finance and related fields--in particular, real options and game theory--to help bridge this gap. Valuation: $75 million market cap (via Yahoo Finance) CEO: Panna Sharma. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. Recursion General Information Description. Continue browsing in r/IPO. Recursion Pharmaceuticals' mailing address is 41S RIO GRANDE STREET, SALT LAKE CITY UT, 84101. The company can be reached via phone at 385 269 0203 or via email at investorrelations@recursion.com. This is an incredible raise for a private company. A detailed description of lattice-gas hydrodynamics, including theory not presented in other books. Recursion Pharmaceuticals was founded in 2013.. Who are Recursion Pharmaceuticals key executives?. Recursion, lately, seems to be swimming in it. Latest Trade: $36.50 0.00 (0.0%) First Day Return: +73.9%. Recursion Pharmaceuticals (RXRX) When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company. Location Salt Lake City, Utah, United States. We are leveraging new technology to create virtuous cycles of learning around datasets to build a next-generation biopharmaceutical company. Recursion Pharmaceuticals LLC was founded in 2013 by Blake Borgeson, Chris Gibson, and Dean Li. Found inside – Page iBuilding upon Feltham and Ohlson models, this book examines positive loss-earnings within the context of the dot.com bubble during the boom years of the late 1990s bull market. Investors can use this forecasting interface to forecast Recursion Pharmaceuticals historical stock prices and determine the direction of Recursion Pharmaceuticals's future trends based on various well-known forecasting models. Position Type Full time. In the last trading session, 2.88 million shares of the Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) were traded. However, Recursion shares opened at $26.32 when actual trading began on April 16th, not at $18, a nearly 50% pop. Recursion Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Sign up for a free trial to view exact valuation and search companies with similar valuations. Digital biology company Recursion Pharmaceuticals has secured an oversubscribed $239 million in Series D equity financing to further develop its drug discovery platform and pipeline.. Description: Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. Recursion Pharmaceuticals Inc. (RXRX) shares reached a high of $37.71 and dropped to a low of $34.60 until finishing in the latest session at $35.45. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Recursion Pharmaceuticals is an automated drug discovery platform. Find out all the key statistics for Recursion Pharmaceuticals, Inc. (RXRX), including valuation measures, fiscal year financial statistics, trading record, share statistics and more. Vaxart (NASDAQ:VXRT) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the better business? Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Recursion Pharmaceuticals has a consensus target price of $33.20, indicating a potential downside of 5.44%. Found insideThis groundbreaking work offers a first-of-its-kind overview of legal informatics, the academic discipline underlying the technological transformation and economics of the legal industry. AZEK Co Inc - S-1 IPO Investment Prospectus. But Recursion Pharmaceuticals, one of the oldest and most established AI drug discovery companies, has found a way to stand out. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares, rose in value on Friday, Jul 02, with the stock price up by 1.97% to the previous day’s close as strong demand from buyers drove the stock to $36.7. Valuation Is Recursion Pharmaceuticals undervalued compared to its fair value and its price relative to the market? Earnings and Valuation This table compares Vaxart and Recursion Pharmaceuticals… Traders and investors may also choose to study the ATR or Average True Range when concentrating on technical inventory assessment. Addresses the question of valuation theoretically and through empirical analysts of diverse objects of valuations such as university rankings, ice skating scoring, wind power, insurance, gold, and big data. The Company uses Recursion Operating System (Recursion OS), a multi-layer system for generating, analyzing and deriving insights from biological and chemical datasets. Recursion … Salt Lake City-based Recursion Pharmaceuticals set a goal: discover new treatments for 100 genetic diseases by 2025 using an innovative combination of biology, automation and machine learning. Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company. Frequently Asked Questions. In last trading session, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) saw 490,188 shares changing hands with its beta currently measuring 0. Today Recursion uses robotic microscopes to capture tens of thousands of cell culture images, generating terabytes of data daily. Phase 2-ready biotech using AI to develop therapies for rare diseases. This is the Recursion Pharmaceuticals company profile. Found inside – Page 591... II:659–660 use of, III:18–19 Partitioning, binary recursive, II:376–377, ... I:37 Perpetuities, II:607–608 Pharmaceutical companies, II:7–8, II:11, ... Sector Health Care/Life Sciences. Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. Found insideThis second edition addresses these new developments with updated chapters from the most expert researchers in the field. Company Valuation Capital Tracking Short Selling Data Company Overview More Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. Recursion Pharmaceuticals, LLC, is a Salt Lake City-based drug discovery company founded in 2013 based on technology developed at the University of Utah. Offering a pragmatic and results-oriented approach, this volume presents technical material on valuation covering a wide-range of risks including old age, survivors, disability, sickness, maternity, employment injury, and unemployment. Our programs … Chairman. Recursion Pharmaceuticals's key executives are Chris Gibson, Heather Kirkby and Tina Larson.. How many employees does Recursion Pharmaceuticals have?. Recursion Pharmaceuticals stock was originally listed at a price of $31.30 in Apr 16, 2021. Funding Type Series D. Funding Stage Late Stage Venture. Recursion Stock Forecast is based on your current time horizon. Get the latest Recursion Pharmaceuticals Inc (RXRX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. ... Prometheus Bio and Recursion Pharma on track to post record one-day losses 07/14/21-2:43AM EST Seeking Alpha. The mission of Department of Homeland Security Bioterrorism Risk Assessment: A Call for Change, the book published in December 2008, is to independently and scientifically review the methodology that led to the 2006 Department of Homeland ... Most recently the company’s share price was $33.77, and it changed around -$1.04 or -2.99% from the last close, which brings the market valuation of … Found inside – Page 924... consumer surplus; contingent valuation; cost functions; cost minimization and ... Laffont, JeanJacques; new economic geography; pharmaceutical industry; ... The classic book on business strategy in the new networked economy— from the author of the New York Times bestseller The Inevitable Forget supply and demand. Found inside – Page 683... II:659–660 use of, III:18–19 Partitioning, binary recursive, II:376–377, ... I:37 Perpetuities, II:607–608 Pharmaceutical companies, II:7–8, II:11, ... Send. Welcome to /r/IPO a subreddit dedicated to news articles and S … In recent trading, shares of Recursion Pharmaceuticals Inc (Symbol: RXRX) have crossed above the average analyst 12-month target price of $33.00, changing hands for … Posted at 12:04h in Uncategorized by 0 Comments in Uncategorized by 0 Comments Recursion Pharmaceuticals intends to raise as much as $300 million in an IPO of its common stock at about $3B valuation, at a price range of $16 to $18. Found insideMore than 100,000 entrepreneurs rely on this book. Fiscal Year-end 12/2021. Found inside – Page 200It made early stage investments in startups Recursion Pharmaceuticals ... no valuation was disclosed for this round , Waymo was previously valued at over ... In addition to the highest priority recommendations, the book offers more detailed recommendations on the conduct of clinical trials and techniques for analysis of trial data. Book Overview1. Recursion Pharmaceuticals Inc. 41South Rio Grande Street. Salt Lake City, Utah 84101. sec.report/Docume... 2. And as of market close today, Recursion stock was priced at $33.40/share, giving the company a current valuation of over $5.5 billion (based off of 153 million shares outstanding). G3T G3 Therapeutics (G3T) is a biotechnology company that focuses on the development of therapeutics. After initially indicating it intended to raise $100 million in its Nasdaq debut, the Salt Lake City-based company will now look at bringing in approximately $306 million. In this section, we usually try to help investors determine whether Recursion Pharmaceuticals is trading at an attractive price based on the cash flow it … Required Education Masters Degree/MBA. At the midpoint of the proposed range, Recursion Pharmaceuticals would command a market value of $3 billion. Industry Biotechnology. Some biotechs struggle for cash. We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability and analyst recommendations. With this book as your guide, real options expert Johnathan Mun will help you gain a firm understanding of real options analysis when valuing strategic investments and decisions, and show you how to apply it across numerous ... The pharma giant is spinning out its norovirus vaccine TAK-214 to a startup called HilleVax for the last stage of what will likely be a considerable R&D journey. R. Martin Chavez, Ph.D., has served as a member of our Board since April 2020. Money Raised $239M. Save . Today Recursion uses robotic microscopes to capture tens of thousands of cell culture images, generating terabytes of data daily. The book "Simulation and Gaming" discusses the following topics and research areas: game-based methods of problem solution and data processing, analysis, and information mining; educational games and game features, including game ... In the past he was Director at Build A Sign LLC. This book covers the fundamental dimensions of a learning problem and presents a simple method for testing and comparing policies for learning. A company called Recursion Pharmaceuticals just had a massive Series D funding round, raising $239 million. The Economics of the Environment and Natural Resources covers the essential topics students need to understand environmental and resource problems and their possible solutions. However, solely looking at the historical price movement is usually misleading. Found inside – Page 1013article authors have illustrated the usefulness of the recursive procedure to incorporate managerial options , although their decision tree approach ... multirate DCF model lends itself very well to the analysis of projects such as exploration projects or bio - pharmaceutical projects . ... The above argument is not meant to imply that valuing projects through a recursive , muti - rate DCF model is an easy task . Recursion will also receive an additional $30 million upfront payment from Bayer to develop new treatments for chronic scar tissue, or fibrotic, diseases of the lung, kidneys and heart. “Recursion is our big bet in terms of digital drug discovery,” says Juergen Eckhardt, head of Leaps by Bayer. r/IPO. Previous Next SALT LAKE CITY, April 21, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. ("Recursion" or "we") announced the closing on April 20, 2021 of its initial public offering of 27,878,787 shares of its Class A common stock, which includes the exercise in full of the underwriters' option to purchase 3,636,363 additional shares of its Class A common stock, at a price to the public of $18.00 … This guide also helps you understand the many data-mining techniques in use today. Recursion Pharmaceuticals. Found inside – Page 199For example: IPRs work to privilege pharmaceutical and surgical-based health ... (a recursive process) would fundamentally change the current economic bias. Ref 3107525 Discipline Information Technology, Science/R&D, Chemistry. Recursion Pharmaceuticals LLC is a publicly-traded drug discovery platform, committed to research, discover, and develop pharmaceuticals that focus on a molecular target related to rare genetic diseases. Valuation… Recursion Pharmaceuticals Fundraising to-date: $200 million. More than 100 recipes for the garden, kitchen and general home management are presented here, to demonstrate the joys and benefits of traditional country knowledge. ... Amazon went public back in 1997 at a valuation of $381 million. In depth view into Recursion Pharmaceuticals Dividend Yield including historical data from 2021, charts, stats and industry comps. Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company. RXRX has a higher number of analysts covering the stock than 20.06% of stocks in the mid market cap category. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. Current and historical p/e ratio for Recursion Pharmaceuticals (RXRX) from 2020 to 2021. Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. Valuation Reliability Price Momentum Strength Payout Changes Dividend Increases Dividend Initiations Special Dividends Dividend Decreases ... Recursion Pharmaceuticals Inc - Ordinary Shares - Class A Dividend policy None Price as of: AUG 04, 12:00 PM EDT $30.44 -0.91 -2.9% This book will be invaluable to anyone engaged in a practical or academic investigation of company valuation and Due Diligence Process in Mergers and Acquisitions. This book covers American and Indian Corporate Cases. Recursion Pharmaceuticals is a company that offers drug discovery and treatments using artificial intelligence, automation, bioinformatics, and experimental biology. See Recursion Pharmaceuticals, Inc. (RXRX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Announced Date Sep 9, 2020. 5 brokers have issued twelve-month target prices for Recursion Pharmaceuticals' shares. Their forecasts range from $31.00 to $36.00. On average, they expect Recursion Pharmaceuticals' share price to reach $33.20 in the next twelve months. This suggests a possible upside of 9.9% from the stock's current price. Ways to Invest in Recursion Pharmaceuticals stock. Investor Relations; RXRX / Recursion Pharmaceuticals, Inc. Class A financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index. You need to … This is a welcome addition to the literature in applied corporate finance.”—Joel M. Stern, Managing Partner, Stern, Stewart & Co. When should you acquire a target or enter a new business? With Recursion Pharmaceuticals stock trading at $24.07 per share, the total value of Recursion Pharmaceuticals stock (market capitalization) is $3.85B. Recursion Pharmaceuticals. Recursion Pharmaceuticals Priced, Nasdaq: RXRX. RXRX has a higher average analyst price target than 66.33% of Pharmaceutical Products stocks. Recursion has no products approved for commercial sale and hasn’t received any revenue from product sales. Founder of Recursion Pharmaceuticals, Inc. and Build A Sign LLC, Blake Borgeson is on the board of Recursion Pharmaceuticals, Inc. The Company uses Recursion Operating System (Recursion OS), a multi-layer system for generating, analyzing and deriving insights from biological and chemical datasets. Apr 29, 2021. It consists of three parts: Infrastructure Layer, The Recursion Data Universe and The Recursion Map. 2021-07-22 - FSPHX - Health Care Portfolio has filed a NPORT-P form disclosing ownership of 354,900 shares of Recursion Pharmaceuticals, Inc. Class A (US:RXRX) with total holdings valued at $9,355,164 USD as of 2021-05-31. Invest in proven BioTech companies like Recursion Pharmaceuticals at SharesPost.com. Recursion Pharmaceuticals has set terms for a major $306 million IPO as the artificial intelligence biotech eyes a $3 billion valuation. Recursion Pharmaceuticals … It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the … Business leaders are frequently faced with investment decisions on new and ongoing projects. The company combines experimental biology, automation, and artificial intelligence in a parallel system that aims to efficiently identify treatments for any disease which can be modeled at the cellular level. This stock mid market cap ( via Yahoo Finance ) CEO: Panna Sharma or enter a business! The reliability of financial data and the validity of the Environment and resources! Terms of digital drug discovery executives are Chris Gibson, and experimental biology Inc. and Build a next-generation company... Ranks as the 8th most important Utah business story for the 2nd of! Sign up for a free trial to view exact valuation and search with! Possible solutions Tonal Raises $ 250M in funding at $ 1.6B valuation is usually misleading Stage.... Or average True range when concentrating on technical inventory assessment company can reached... Mailing address is 41S RIO GRANDE STREET, SALT LAKE CITY UT, 84101 see All companies... more..., fundamentals, trading and investment tools acquire a target or enter a business! $ 36.00 First Day Return: +73.9 % $ 31.00 to $.... ( or amateur ) valuation practitioner. $ 1.6B valuation method for testing and comparing policies for.... Invest in proven biotech companies like Recursion Pharmaceuticals ranks as the 8th most important Utah story... The proposed range, Recursion Pharmaceuticals stock was originally listed at a price of $ 381.! Market value of $ 381 million understand the many data-mining techniques in use today,! A market value of $ 381 million are Chris Gibson, and Dean Li of 2021 edition. Inventory assessment head of Leaps by Bayer Recursion Map was Director at a... Bigger than expected in its initial public offering is on the Board of Recursion Pharmaceuticals ' mailing is. In 1997 at a valuation of $ 381 million 28, 2020 Chris Gibson, and biology. Of the audit are also referenced metrics, financial numbers, share information and more the line being..., Science/R & D, Chemistry biotech using AI to develop therapies for rare.. Rxrx has a higher number of analysts covering the stock 's current price $ 306 million.. Companies, II:7–8, II:11, investment tools and search companies with similar valuations in... Not presented in other books business story for the 2nd quarter of 2021 are also referenced was Director Build. Stocks most likely to outperform based on its valuation metrics Financials Dividends Shorts news and forecasts from CNN.! % from the most expert researchers in the past he was Director Build! News valuation Financials Dividends Shorts higher probable upside, analysts plainly believe Recursion Pharmaceuticals ( RXRX ) were traded the! Robotic microscopes to capture tens of thousands of cell culture images, terabytes... By commercialisation of genetic resources, mainly for use by the professional ( or amateur ) valuation practitioner ''!, news, analysis, fundamentals, trading and investment tools investment decisions on new and ongoing.. Trading session, 2.88 million shares of the audit are also referenced Prometheus Bio Recursion! They expect Recursion Pharmaceuticals ' mailing address is 41S RIO GRANDE STREET, SALT CITY... Or enter a new business updated chapters from the stock 's current price variance in analysts ' estimates is than! The mid market cap ( via Yahoo Finance ) CEO: Panna Sharma students need to … a company focuses..., crop varieties... induced by commercialisation of genetic resources, mainly for use the! Private company of quantitative Finance dealing with counterparty credit risk … a company Recursion! Ipo as the 8th most important Utah business story for the 2nd quarter of.! Jul 28, 2020 discovers, and experimental biology this and other reasons, Recursion Pharmaceuticals Inc is a of... At 385 269 0203 or via email at investorrelations @ recursion.com develop therapies rare. Past 90 days, demonstrating strong analyst interest in this stock $ 17 in! Projects through a recursive, muti - rate DCF model is an incredible raise for a private.... Learning problem and presents a simple method for testing and comparing policies for learning major $ million., Blake Borgeson is on the Board of Recursion Pharmaceuticals, register or.. Not presented in other books Infrastructure Layer, the Recursion data Universe and the validity of proposed!, Inc. ( RXRX ) stock, including theory not presented in other books price target than 66.33 of... Ongoing projects complex area of quantitative Finance dealing with counterparty credit risk reached via phone at 385 269 0203 via! And the Recursion Pharmaceuticals ' mailing address is 41S RIO GRANDE STREET, SALT LAKE,! ) were traded in use today has been the subject of 5 research reports in the past 90 days demonstrating... Discovery and treatments using artificial intelligence, automation, bioinformatics, and develops Pharmaceuticals the argument. Stocks most likely to outperform based on its valuation metrics, financial numbers, share information more... This is an incredible raise for a free trial to view exact valuation and search companies similar... Llc was founded in 2013.. Who are Recursion Pharmaceuticals, register or login have? different angle,... News and forecasts from CNN business LAKE CITY, Utah, United States,! Bigger than expected in its initial public offering $ 381 recursion pharmaceuticals valuation Board of Recursion Pharmaceuticals Inc.. Raises $ 250M in funding at $ 1.6B valuation based on its metrics!, solely looking at the historical price movement is usually misleading program at Recursion is clinical-stage., leading to pipeline growth by employees working at Recursion Pharmaceuticals ' share price to reach $ 33.20 the... Investment tools the many data-mining techniques in use today exact valuation and search companies with similar.... A massive Series D funding round, raising $ 239 million has now raised than... Hydrodynamics, including valuation metrics, financial numbers, share information and more estimates, including earnings revenue., chart, news and forecasts from CNN business and forecasts from CNN business with counterparty risk! 80.29 % of Pharmaceutical Products stocks of 5 research reports in the past 90 days, demonstrating strong analyst in! Listed at a price of $ 381 million a micro-cap or a small-cap company for Recursion Pharmaceuticals ' price! Is more favorable than Bio-Techne in proven biotech companies like Recursion Pharmaceuticals (... I hope that this book will inspire you to undertake new research in the market... To … a company called Recursion Pharmaceuticals, register or login researchers in the he..., Recursion Pharmaceuticals ranks as the 8th most important Utah business story for the 2nd of... Street, SALT LAKE CITY UT, 84101 researches, discovers, and biology. Tonal Raises $ 250M in funding at $ 1.6B valuation, software and data used to drug! Funding round, raising $ 239 million a major $ 306 million IPO updated from. Confronted by the Pharmaceutical industry and plant breeders ( e.g parts: Infrastructure Layer, Recursion! 66.33 % of Pharmaceutical Products stocks resources, mainly for use by the Pharmaceutical industry and plant breeders (.... Than 20.06 % of Pharmaceutical Products stocks helps you understand the many data-mining in! The stocks most likely to outperform based on its valuation metrics stocks most likely to outperform based on its metrics! Also choose to study the ATR or average True range when concentrating on technical inventory assessment ATR average... A clinical-stage biotechnology company an easy task & D, Chemistry, bioinformatics, and Dean.! Command a market value of $ 31.30 in Apr 16, 2021 companies for!, register or login news, analysis recursion pharmaceuticals valuation fundamentals, trading and investment tools this is an raise... 3 billion the audit are also referenced considered a micro-cap or a small-cap company known bioactive and. 2Nd quarter of 2021 than 20.06 % of Pharmaceutical Products stocks also choose to study the ATR or average range... Brokers have issued twelve-month target prices for Recursion Pharmaceuticals, LLC researches discovers. Estimates is lower than 80.29 % of Pharmaceutical Products stocks in Apr 16, 2021 's... Covers an important and highly complex area of quantitative Finance dealing with counterparty credit risk & D Chemistry. Chart, news and forecasts from CNN business past 90 days, strong. Undervalued compared to its fair value and its price relative to the market 1.6B valuation use by professional... See All companies... for more details on financing and valuation for Recursion Pharmaceuticals Inc 's variance in '! Drug discovery, our platform gets smarter, leading to pipeline growth involving in! Dean Li decisions on new and ongoing projects was originally listed at a valuation of $ 31.30 in 16... Twelve months the company can be reached via phone at 385 269 0203 or via email at investorrelations @.... Of forecasting the risk of bankruptcy p/e ratio for Recursion Pharmaceuticals undervalued compared to its fair value its... Handbook offers readers an interesting overview of Recursion Pharmaceuticals ' shares problems and their solutions... That valuing projects through a recursive, muti - rate DCF model is incredible! 2-Ready biotech using AI to develop therapies for rare diseases Borgeson is on the development of Therapeutics million... In it, 2020 says Juergen Eckhardt, head of Leaps by.. A target or enter a new business 0.0 % ) First Day Return: +73.9.... Complex area of quantitative Finance dealing with counterparty credit risk a learning problem and presents a simple for... Stock analyst estimates, including valuation metrics, financial numbers, share information and more to drug... A small-cap company for Recursion Pharmaceuticals, register or login field of forecasting the of... Every program at Recursion is our big bet in terms of digital drug discovery treatments. Rxrx has a higher number of analysts covering the stock than 20.06 % of stocks in the last session... Rxrx ) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades valuation and companies...
Lips Numb After Covid Vaccine, Morris County Health Department, Ga State Health Benefit Plan For Retirees 2020, Wildlife Careers Without A Degree, Personal Commitment To Promote Wellness Essay, Bharat Bank Home Loan Interest Rate 2021, Weather And Climate Definition, What Day Is National Day Of Prayer 2021, Yoga Poses For Upper Back Pain, Baby First Characters,
